Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (20391)	4/12/1999 12:51:00 PM
From: RT	Read Replies (2) \| Respond to of 23519

VLAD, Why don't you apply for a job with VVUS? You know more about the company than Leland and I know of no one who is more knowledgeable about the ED market and is totally biased. You would make an outstanding PR man and you would serve us investors well. I do have one question. Do you have crooked teeth? RT

To: VLAD who wrote (20391)	4/12/1999 8:07:00 PM
From: Edderd	Read Replies (1) \| Respond to of 23519

VLAD Got this today on UrologyFax. Vivus inc. has been issued broad protection for the commercialization of Alibra, its second generation transurethral treatment for male erectile dysfunction (ED). This is the first transurethral two-drug treatment to treat erectile dysfunction, uses alprostadil and prazosin to initiate and maintain smooth muscle relaxation. This product, currently in phase-lll trials, features a redisigned applicator and a single-strength formulation. Ineresting Eh. I hope its a gel you squeeze into the urethra. With a single dose it would really be easy to use. Note that a gel could be applied to a female _______. How about that idea. Ed